<DOC>
	<DOCNO>NCT00537485</DOCNO>
	<brief_summary>To investigate superiority SPM 962 placebo early Parkinson 's disease patient multi-center , placebo-controlled , double-blind study follow once-daily multiple transdermal dos SPM 962 within range 4.5 36.0 mg ( 12-week dose titration/maintenance period )</brief_summary>
	<brief_title>A Placebo-controlled Study SPM 962 Early Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1 . Subject diagnose Parkinson 's disease accordance `` Diagnostic Criteria establish Research Committee MHLWspecified Intractable Neurodegenerative Diseases ( 1995 ) '' 2 . Subject 30 year &lt; &gt; 80 year time inform consent 3 . Hoehn &amp; Yahr stage 1 3 4 . Total sum score UPDRS Part 2 3 10 screen test 1 . Subject previously participate trial SPM 962 2 . Subject Ldopa treatment total 6 month time inform consent 3 . Subject psychiatric symptom , e.g . confusion , hallucination , delusion , excitation , delirium , abnormal behavior screen test baseline 4 . Subject orthostatic hypotension 5 . Subject history epilepsy , convulsion 6 . Subject complication serious cardiac disorder/arrhythmia history 7 . Subject arrhythmia treat class 1a antiarrhythmic drug ( e.g . quinidine , procainamide etc . ) class 3 antiarrhythmic drug ( e.g . amiodarone , sotalol etc . ) 8 . Subject serious ECG abnormal screen i.e . ; 1 ) Subject 450 msec QTc value two measurement screen test 2 ) Subject 470 msec female 450 msec male mean QTc value two measurement baseline 9 . Subject congenital long QT syndrome 10 . Subject serum potassium le 3.5 mEq/L screen test . 11 . Subject total bilirubin 3.0 mg/dL AST ( GOT ) , ALT ( GPT ) great 2.5 time ( 100 IU/L ) clinical laboratory 's upper limit reference range screen test 12 . Subject 30 mg/dL BUN 2.0 mg/dL serum creatinine screen test 13 . Subject history allergy topical medicine , e.g . transdermal patch 14 . Subject pregnant , nursing , child bear potential trial 15 . Subject receive therapy prohibit drug specify study protocol 16 . Subject history pallidotomy , thalamotomy , deep brain stimulation fetal tissue transplant 17 . Subject dementia 18 . Subject unable give consent 19 . Subject participate another trial investigational drug do within 12 week prior initial treatment 20 . Investigator judge subject inappropriate study subject reason</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>monotherapy</keyword>
</DOC>